Clinical Protocol: Administration of Neomycin Resistance Gene-Marked EBV-Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving a Bone Marrow Transplant for Relapsed EBV-Positive Hodgkin Disease.-Reference-Cited by-同舟云学术

Clinical Protocol: Administration of Neomycin Resistance Gene-Marked EBV-Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving a Bone Marrow Transplant for Relapsed EBV-Positive Hodgkin Disease.

Published:2000-07 Issue:10 Volume:11 Page:1465-1475
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/10430340050057530

Reference7 articles.

1. Immunobiology of CR2, the B Lymphocyte Receptor for Epstein-Barr Virus and the C3d Complement Fragment

2. Epstein-Barr virus strategy in normal and neoplastic B cells

3. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Nuances of Precision Molecular Engineering for Hodgkinâs Disease to a Gene Therapeutic Approach;Critical Reviews in Immunology;2024

2. Gene-modified, cell-based therapies—an overview;Cytotherapy;2016-11

3. Preventing stem cell transplantation-associated viral infections using T-cell therapy;Immunotherapy;2015-07

4. Viral DNA contamination is responsible for Epstein–Barr virus detection in cytotoxic T lymphocytes stimulated in vitro with Epstein–Barr virus B-lymphoblastoid cell line;Cancer Immunology, Immunotherapy;2010-08-31

5. T-cell genetic modification for re-directed tumor recognition;Cancer Chemotherapy and Biological Response Modifiers Annual;2005